Biomea Fusion, Inc. announced positive clinical data from the Phase II portion of its clinical trial for its lead product candidate, BMF-219, in type 2 diabetes.
AI Assistant
BIOMEA FUSION INC
2023
8 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.